We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Therapeutic Strategy for Microplastics and Nanoplastics: A Systems-Level Framework for Mitigation, Inflammation, and Companion Diagnostics
Summary
Tiny plastic particles from our environment may be quietly triggering inflammation and disrupting normal body functions in our gut, brain, and other systems—not just sitting harmlessly inside us. A biotech company called Cythera Bio is developing a new approach to tackle this problem: instead of trying to break down the plastic itself, they're working on ways to trap these particles, stop them from interacting with our cells, and calm the inflammation they cause. This is still an early-stage strategy (not yet proven treatments), but it points toward possible future products—both wellness supplements and medical treatments—to help protect our bodies from plastic p
Abstract Microplastics and nanoplastics (MPs/NPs) are increasingly recognized as biologically active environmental particulates capable of interacting with multiple organ systems. While current research has largely focused on environmental detection and polymer degradation, emerging evidence suggests that chronic particulate exposure may contribute to inflammation, barrier dysfunction, immune dysregulation, and altered biological signaling across gastrointestinal, neurological, metabolic, and systemic pathways. Cythera Bio is developing a systems-level therapeutic framework focused on reducing the biological impact of MPs/NPs through interaction-mediated mitigation, inflammatory modulation, and biologically adaptive therapeutic architectures. Rather than relying exclusively on polymer degradation, this framework emphasizes reduction of particle interaction potential through aggregation, sequestration, altered transport dynamics, barrier stabilization, and modulation of downstream inflammatory pathways. The company is pursuing both wellness-oriented exposure support products and FDA-regulated therapeutic programs spanning gastrointestinal disease, neuroinflammation, aging-associated dysfunction, and systemic inflammatory biology. Companion diagnostic and monitoring frameworks may further support exposure characterization and future adaptive therapeutic strategies.